ReviewBoneKEy reports2015
Tumour-derived miRNAs and bone metastasis.
Review in BoneKEy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.Cancers · 2021Article
- MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma.Cancers · 2021Article
- microRNA Prognostic Signature for Postoperative Success of Metastatic Orthopedic Cancers: Implications for Precision Microsurgery.Frontiers in cell and developmental biology · 2021Article
- Role of the bone microenvironment in bone metastasis of malignant tumors - therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- Review
- Circulating MicroRNAs and Blood-Brain-Barrier Function in Breast Cancer Metastasis.Current pharmaceutical design · 2020Article
- Molecular mechanisms and clinical management of cancer bone metastasis.Bone research · 2020Review
- [Progress of Biomarkers in Diagnosis of Bone Metastases of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Review
- Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma.World journal of gastroenterology · 2018Article
- Mesenchymal Stromal Cells: Emerging Roles in Bone Metastasis.International journal of molecular sciences · 2018Review
- Targeting the Metastatic Bone Microenvironment by MicroRNAs.Frontiers in endocrinology · 2018Review
- MicroRNAs in bone diseases.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Review
- Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells.Oncotarget · 2016Article
- Cancer Cell Colonisation in the Bone Microenvironment.International journal of molecular sciences · 2016Review
- The role of osteoclasts in breast cancer bone metastasis.Journal of bone oncology · 2016Article
- Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?International journal of molecular sciences · 2016Review
- Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.Nature reviews. Rheumatology · 2016Review
- MicroRNA Regulation of Human Breast Cancer Stem Cells.Journal of clinical medicine · 2015Review
- Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma.BoneKEy reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal metastases are complications of epithelial cancers, among which breast, prostate and lung carcinomas are the most osteotropic. In primary tumours, a subset of cancer cells undergoes epithelial-mesenchymal transition, acquires mobility to migrate into the surrounding stroma and seeds at distant sites to grow. The specific development of bone metastasis requires the recruitment of circulating tumour cells in the bone marrow, their adaptation to survive in the surrounding microenvironment where they alter the functions of osteoclasts and osteoblasts, and hijack signals coming from the bone matrix. Each of the molecular pathways underlining these steps is regulated by multiple factors, through the tight control of genes expressed by cancer cells interacting with cells from the bone microenvironment. In this context, miRNAs can act as master regulators of gene expression to control multiple aspects of bone metastasis formation, including cancer cell escape from the primary tumour site, cancer cell dissemination to bone and invasion of the bone marrow, as well as secondary outgrowth and tumour-stroma cell interactions. In the clinic, specific miRNA signatures have been identified in osteotropic cancer cells, raising the possibility that miRNAs could be used as biomarkers of bone metastasis. The regulatory activity of miRNAs in the bone microenvironment also suggests that miRNAs could be promising therapeutic targets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.